A Comparative Assessment of Immunological Parameters in HIV-HCV Coinfected Patients on Art-With and Without Treatment for HCV

Among HIV-HCV co-infected patients all patients cannot afford the treatment of HCV. The aim is to study the natural history of disease in HIV-HCV co-infected patients on Anti Retroviral Therapy( ART) who could not take treatment for HCV. We hypothesized that Anti Retroviral Therapy will help in decreasing the disease progression of HCV and there will not be much difference in prognosis who are additionally treated with anti HCV drugs. Methods: 145 patients are included in this study who are HIV HCV co-infected who are on ART. Only 40 patients has been treated for HCV in some point of their life. We compared the immunological profile of two groups and paired t test was used to compare it. CD4 count was calculated by Fluorescence Activated Cell sorter. Results: Mean CD4 count was higher in treated group(p-0.0013) showing better immunological status in treated patients. HCV RNA count(p-0.0001) was also higher in non treated group. Conclusion: There is a better immunological profile in HCV treated than in non treated patients indicating the importance of early treatment for hepatitis C in HIV-HCV co-infection.

[1]  N. Singh,et al.  A Comparative Assessment of Immunological Parameters in HIV-HCV Coinfected Patients on Art-With and Without Treatment for HCV , 2018 .

[2]  B. Akoijam,et al.  High burden of hepatitis C & HIV co-infection among people who inject drugs in Manipur, Northeast India , 2016, The Indian journal of medical research.

[3]  R. Aggarwal,et al.  Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India. , 2014, Journal of clinical and experimental hepatology.

[4]  Ajit Kumar,et al.  Hepatitis B and/or C co-infection in HIV infected patients: A study in a tertiary care centre from south India , 2013, The Indian journal of medical research.

[5]  Kurt J.isselbacher,et al.  Harrison's principle of internal medicine , 2012 .

[6]  G. Dore,et al.  What Is Killing People with Hepatitis C Virus Infection? , 2011, Seminars in liver disease.

[7]  Venkatesan Chakrapani,et al.  Social-structural contexts of needle and syringe sharing behaviours of HIV-positive injecting drug users in Manipur, India: a mixed methods investigation , 2011, Harm reduction journal.

[8]  M. Muñoz-Fernández,et al.  Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients? , 2010, BMC infectious diseases.

[9]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[10]  C. Latkin,et al.  Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case–control study , 2009, AIDS care.

[11]  D. Vlahov,et al.  Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. , 2004, International journal of epidemiology.

[12]  M. Sulkowski,et al.  Hepatitis C in the HIV-Infected Person , 2003, Annals of Internal Medicine.

[13]  J. Hoofnagle.  Course and outcome of hepatitis C , 2002, Hepatology.

[14]  D. Vlahov,et al.  Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland , 1997, Journal of clinical microbiology.

[15]  D. Vlahov,et al.  Correlates of Hepatitis C Virus Infections among Injection Drug Users , 1995, Medicine.

[16]  J. Goedert,et al.  Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. , 1993, Journal of acquired immune deficiency syndromes.